Lexeo Therapeutics reports progress in US FDA discussions for accelerated approval pathway for LX2006 in Friedreich ataxia cardiomyopathy: New York Saturday, October 11, 2025, 16: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback